Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Rilpivirine (Edurant®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml, in combination with other antiretroviral medicinal products. |
|||
|
|||
Medicine details |
|||
| Medicine name | rilpivirine (Edurant®) | ||
| Formulation | 25 mg film-coated tablet | ||
| Reference number | 557 | ||
| Indication | In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment naïve adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 1312 | ||
| NMG meeting date | 15/05/2012 | ||
| AWMSG meeting date | 20/06/2012 | ||
| Ratification by Welsh Government | 23/07/2012 | ||
| Date of issue | 27/07/2012 | ||
| Date of last review | November 2022 | ||
| Further information This appraisal recommendation was reviewed in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |
|||
| Scrutiny Panel meeting date | useMuraDefault | ||
| LOWMAG meeting date | useMuraDefault | ||
| OWMAG meeting date | useMuraDefault | ||